» Articles » PMID: 16404573

Immunohistochemical and in Situ Hybridization Analysis of Galectin-3, a Beta-galactoside Binding Lectin, in the Urinary System of Adult Mice

Overview
Publisher Springer
Date 2006 Jan 13
PMID 16404573
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Galectin is an animal lectin that has high affinity to beta-galactoside of glycoconjugates. In the present study, cellular expression of galectin subtypes in the urinary system of adult mice was examined by in situ hybridization and immunohistochemistry. The major subtype expressed in the murine urinary system was galectin-3, which was expressed continuously from the kidney to the distal end of the urethra. The renal cortex expressed galectin-3 more intensely than the medulla. Renal galectin-3 immunoreactivity was strongest in the cortical collecting ducts, where principal cells were the sole cellular source. All cell layers of the transitional epithelium from the renal pelvis to the urethra strongly expressed galectin-3 at the mRNA and protein levels. An electron microscopic study demonstrated diffuse cytoplasmic localization of galectin-3 in principal cells of the collecting ducts and in the bladder epithelial cells. Urethral galectin-3 expression at the pars spongiosa decreased in intensity near the external urethral orifice, where the predominant subtype of galectin was substituted by galectin-7. The muscular layer of the ureter and urinary bladder contained significant signals for galectin-1. Taken together, the observations indicate that the adult urinary system shows intense and selective expression of galectin-3 in epithelia of the uretic bud- and cloaca-derivatives.

Citing Articles

Galectin-3 as a Potential Biomarker of Microvascular Complications in Patients with Type 2 Diabetes.

Kumar S, Ranawat C, Bhandiwad C, Arya H, Mali M, Singh C Indian J Endocrinol Metab. 2023; 26(5):490-497.

PMID: 36618522 PMC: 9815198. DOI: 10.4103/ijem.ijem_270_22.


The interferon-β/STAT1 axis drives the collective invasion of skin squamous cell carcinoma with sealed intercellular spaces.

Kumagai Y, Nio-Kobayashi J, Ishihara S, Enomoto A, Akiyama M, Ichihara R Oncogenesis. 2022; 11(1):27.

PMID: 35606369 PMC: 9126940. DOI: 10.1038/s41389-022-00403-9.


Galectin-3 in Kidney Diseases: From an Old Protein to a New Therapeutic Target.

Boutin L, Depret F, Gayat E, Legrand M, Chadjichristos C Int J Mol Sci. 2022; 23(6).

PMID: 35328545 PMC: 8952808. DOI: 10.3390/ijms23063124.


A novel immunofluorescence detection method for renal cell-type specific in situ cytokine production by confocal microscopy.

Sung S, Fu S MethodsX. 2020; 7:100935.

PMID: 32577408 PMC: 7303990. DOI: 10.1016/j.mex.2020.100935.


Uromodulin regulates renal magnesium homeostasis through the ion channel transient receptor potential melastatin 6 (TRPM6).

Nie M, Bal M, Liu J, Yang Z, Rivera C, Wu X J Biol Chem. 2018; 293(42):16488-16502.

PMID: 30139743 PMC: 6200953. DOI: 10.1074/jbc.RA118.003950.


References
1.
Huflejt M, Jordan E, Gitt M, Barondes S, Leffler H . Strikingly different localization of galectin-3 and galectin-4 in human colon adenocarcinoma T84 cells. Galectin-4 is localized at sites of cell adhesion. J Biol Chem. 1997; 272(22):14294-303. DOI: 10.1074/jbc.272.22.14294. View

2.
Shimura T, Takenaka Y, Fukumori T, Tsutsumi S, Okada K, Hogan V . Implication of galectin-3 in Wnt signaling. Cancer Res. 2005; 65(9):3535-7. DOI: 10.1158/0008-5472.CAN-05-0104. View

3.
Pugliese G, Pricci F, Leto G, Amadio L, Iacobini C, Romeo G . The diabetic milieu modulates the advanced glycation end product-receptor complex in the mesangium by inducing or upregulating galectin-3 expression. Diabetes. 2000; 49(7):1249-57. DOI: 10.2337/diabetes.49.7.1249. View

4.
Takenaka Y, Fukumori T, Raz A . Galectin-3 and metastasis. Glycoconj J. 2004; 19(7-9):543-9. DOI: 10.1023/B:GLYC.0000014084.01324.15. View

5.
Woo H, Shaw L, Messier J, Mercurio A . The major non-integrin laminin binding protein of macrophages is identical to carbohydrate binding protein 35 (Mac-2). J Biol Chem. 1990; 265(13):7097-9. View